Full Press Release Details
Ocugen Granted FDA Orphan Drug Designation for OCU400 Gene Therapy for the Treatment of NR2E3 Mutation-Associated Retinal Degenerative Disease.
OCGN
Ocugen Granted FDA Orphan Drug Designation for OCU400 Gene Therapy for the Treatment of NR2E3 Mutation-Associated Retinal Degenerative Disease
Key Takeaway: Ocugen Granted FDA Orphan Drug Designation for OCU400 Gene Therapy for the Treatment of NR2E3 Mutation-Associated Retinal Degenerative Disease